XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Deferred Revenue $ 4,744   $ 15,857
Drug product revenue recognized 60,827 $ 38,429  
Drug Product Revenue [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized 7,594 8,480  
Drug Product Revenue [Member] | Astellas Agreement [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized 7,594 4,030  
Drug Product Revenue [Member] | Astra Zeneca Agreements [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized 0 4,450  
Drug Product Revenue [Member] | Japan [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized 9,800    
Drug Product Revenue [Member] | API Shipment [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized 2,200 $ 4,000  
Bulk Drug Product [Member] | Astellas Agreement [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized 45,500    
Bulk Drug Product [Member] | Astra Zeneca Agreements [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized 11,200    
Bulk Drug Product [Member] | E U Supply And Astellas Agreement [Member] | Europe [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Billed Contracts Receivable $ 49,200